"Caring for the sick took priority over everything else in my husband's life," said Lily Safra. "During his lifetime he helped countless people receive medical treatment and was a generous supporter of scientific research around the world. It is therefore our privilege to be a partner in the Michael J. Fox Foundation's innovative, creative, and strategic efforts to find a cure for Parkinson's disease."
"The Michael J. Fox Foundation has been deeply fortunate to have the unflagging commitment of The Edmond J. Safra Foundation in our shared search for revolutionary treatments for Parkinson's disease," said Katie Hood, MJFF's chief executive officer.
The Edmond J. Safra Core Programs for PD Research, all of which fall at traditionally underfunded stages of the drug development pipeline, are:
Rapid Response Innovation Awards --- a one-of-a-kind, rolling-application program to support groundbreaking Parkinson's disease research in real-time. Rapid Response funds high-risk, high-reward projects within weeks of application, aiming to tackle critical scientific roadblocks and help open new avenues for PD therapy development.
Target Validation --- supports rigorous testing of early-stage discoveries to determine whether they are true targets for commercial therapeutic development. Target Validation projects are structured to conclusively confirm that a biological target plays a role in disease and that by modifying the target, symptoms or disease course can be altered.
Clinical Intervention Awards --- supports projects exploring new neuroprotective treatments, improvements on existing therapies, and development of treatments for unmet symptoms. The program funds proof-of-principle clinical research involving the active participation of small sample populations.
Other MJFF programs also have been made possible by the leadership
generosity of The Edmond J. Safra Foundation. They include the 2007 funding
round of MJFF's signature i
'/>"/>
| SOURCE The Michael J. Fox Foundation for Parkinson?s Research Copyright©2008 PR Newswire. All rights reserved |